- Home
- Publications
- Publication Search
- Publication Details
Title
Bendamustine in multiple myeloma
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 95, Issue 5, Pages 377-388
Publisher
Wiley
Online
2015-06-18
DOI
10.1111/ejh.12609
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKonerandomized dose selection trial
- (2015) Steve Schey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial
- (2015) M.-V. Mateos et al. HAEMATOLOGICA
- Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function
- (2015) Iris Breitkreutz et al. HEMATOLOGICAL ONCOLOGY
- Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma
- (2015) Wolfram Poenisch et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial
- (2015) M.-V. Mateos et al. HAEMATOLOGICA
- Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
- (2014) I-Jun Lau et al. ANNALS OF HEMATOLOGY
- Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
- (2014) P. Rodon et al. HAEMATOLOGICA
- Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma
- (2014) Wolfram Pönisch et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma
- (2013) Tomer M. Mark et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
- (2013) H. Ludwig et al. BLOOD
- Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077
- (2013) Wolfram Pönisch et al. BRITISH JOURNAL OF HAEMATOLOGY
- United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma
- (2013) G. Pratt et al. International Journal of Laboratory Hematology
- Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure
- (2013) Wolfram Pönisch et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
- (2013) M Offidani et al. Blood Cancer Journal
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
- (2012) S. Lentzsch et al. BLOOD
- Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
- (2012) James R. Berenson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
- (2012) Wolfram Pönisch et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone
- (2012) Wolfram Pönisch et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma
- (2011) Elisabeth Grey-Davies et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease
- (2011) Karthik Ramasamy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival
- (2011) Antonio Palumbo et al. CLINICAL CANCER RESEARCH
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program
- (2011) G. Damaj et al. LEUKEMIA & LYMPHOMA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
- (2011) D. Pulte et al. ONCOLOGIST
- Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia
- (2010) A. Elefante et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Bendamustine: something old, something new
- (2010) Nishant Tageja et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma
- (2010) Joel S. Owen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- (2010) Michinori Ogura et al. CANCER SCIENCE
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
- (2010) María-Victoria Mateos et al. LANCET ONCOLOGY
- Bendamustine: Rebirth of an Old Drug
- (2009) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
- (2008) Wolfram Pönisch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
- (2008) G. Roue et al. CLINICAL CANCER RESEARCH
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents
- (2008) L. M. Leoni et al. CLINICAL CANCER RESEARCH
- Identification and Quantitation of the N-Acetyl-L-cysteine S-Conjugates of Bendamustine and Its Sulfoxides in Human Bile after Administration of Bendamustine Hydrochloride
- (2008) J. Teichert et al. DRUG METABOLISM AND DISPOSITION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search